The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jul 2016
Randomized Controlled Trial Multicenter Study Comparative StudyFirst-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia. This international phase 3 study compared the efficacy and tolerance of the standard therapy with a potentially less toxic combination consisting of bendamustine and rituximab. ⋯ Roche Pharma AG, Mundipharma, German Federal Ministry of Education and Research.